Adicet Bio, Inc. (ACET)
- Previous Close
1.4900 - Open
1.5100 - Bid 1.5400 x 200
- Ask 1.5700 x 200
- Day's Range
1.5050 - 1.6300 - 52 Week Range
1.1000 - 5.8100 - Volume
673,022 - Avg. Volume
1,296,195 - Market Cap (intraday)
128.191M - Beta (5Y Monthly) 1.76
- PE Ratio (TTM)
-- - EPS (TTM)
-3.0700 - Earnings Date Aug 7, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.00
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.
www.adicetbio.comRecent News: ACET
Performance Overview: ACET
Trailing total returns as of 5/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACET
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACET
Valuation Measures
Market Cap
127.78M
Enterprise Value
-99.77M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.47
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-27.20%
Return on Equity (ttm)
-53.25%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-139.79M
Diluted EPS (ttm)
-3.0700
Balance Sheet and Cash Flow
Total Cash (mrq)
247.59M
Total Debt/Equity (mrq)
7.74%
Levered Free Cash Flow (ttm)
-57M